{"organizations": [], "uuid": "db0fa2831b9bbb1886818b6fb8b96f2f412bf46b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/axovant-sciences-study/axovant-to-scrap-intepirdine-program-after-dementia-trial-fails-idUSL4N1P33I0", "country": "US", "domain_rank": 408, "title": "Axovant to scrap intepirdine program after dementia trial fails", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.06, "site_type": "news", "published": "2018-01-08T20:26:00.000+02:00", "replies_count": 0, "uuid": "db0fa2831b9bbb1886818b6fb8b96f2f412bf46b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/axovant-sciences-study/axovant-to-scrap-intepirdine-program-after-dementia-trial-fails-idUSL4N1P33I0", "ord_in_thread": 0, "title": "Axovant to scrap intepirdine program after dementia trial fails", "locations": [], "entities": {"persons": [{"name": "savio", "sentiment": "none"}, {"name": "axovant", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}, {"name": "lewy", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "axovant sciences ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Axovant Sciences Ltd said on Monday it would discontinue its intepirdine program after the experimental treatment failed in a mid-stage study on patients suffering from a type of dementia.\nNeither of the two doses of intepirdine given to patients with dementia with Lewy bodies resulted in improving their motor function, compared with patients given a placebo, Axovant said.\nIn September, Axovant stopped testing the drug on patients suffering from Alzheimer’s after a late-stage trial failure. (Reporting by Tamara Mathias in Bengaluru; Editing by Savio D‘Souza)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:26:00.000+02:00", "crawled": "2018-01-09T17:13:34.006+02:00", "highlightTitle": ""}